MedTrace Logo

Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults

NCT02386098 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2018-08-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate whether the combination of BMS-955176 with atazanavir (ATV) \[with or without ritonavir (RTV)\] and dolutegravir (DTG) is efficacious, safe, and well-tolerated in HIV-1 infected treatment experienced adults.

Conditions

  • HIV Infections

Interventions

DRUG

BMS-955176

HIV Maturation Inhibitor

DRUG

Atazanavir (ATV)

Atazanavir

DRUG

Ritonavir (RTV)

Ritonavir

DRUG

Dolutegravir (DTG)

Dolutegravir

DRUG

Tenofovir (TDF)

Tenofovir

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · ViiV Healthcare

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-08
Primary Completion
2017-06-07
Completion
2017-06-07
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Australia
  • Canada
  • Chile
  • Colombia
  • Mexico
  • Peru
  • Puerto Rico
  • Russia
  • South Africa
  • Taiwan
  • Thailand

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02386098 on ClinicalTrials.gov